A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies by Bromage, DI et al.
RESEARCH ARTICLE
A novel recombinant antibody specific to full-
length stromal derived factor-1 for potential
application in biomarker studies
Daniel I. Bromage¤, Stasa Taferner¤, Mahesh Pillai¤, Derek M. Yellon¤, Sean M. Davidson¤*
The Hatter Cardiovascular Institute, University College London, London, United Kingdom
¤ Current address: The Rayne Institute, Lambeth Wing St Thomas’ Hospital, London, United Kingdom
* s.davidson@ucl.ac.uk
Abstract
Background
Stromal derived factor-1α (SDF-1α/CXCL12) is a chemokine that is up-regulated in dis-
eases characterised by tissue hypoxia, including myocardial infarction, ischaemic cardiomy-
opathy and remote ischaemic conditioning (RIC), a technique of cyclical, non-injurious
ischaemia applied remote from the heart that protects the heat from lethal ischaemia-reper-
fusion injury. Accordingly, there is considerable interest in SDF-1α as a potential biomarker
of such conditions. However, SDF-1α is rapidly degraded and inactivated by dipeptidyl pep-
tidase 4 and other peptidases, and the kinetics of intact SDF-1α remain unknown.
Methods & results
To facilitate investigation of full-length SDF-1α we established an ELISA using a novel
recombinant human antibody we developed called HCI.SDF1. HCI.SDF1 is specific to the
N-terminal sequence of all isoforms of SDF-1 and has a comparable KD to commercially
available antibodies. Together with a detection antibody specific to the α-isoform, HCI.SDF1
was used to specifically quantify full-length SDF-1α in blood for the first time. Using RIC
applied to the hind limb of Sprague-Dawley rats or the arms of healthy human volunteers,
we demonstrate an increase in SDF-1α using a commercially available antibody, as previ-
ously reported, but an unexpected decrease in full-length SDF-1α after RIC in both species.
Conclusions
We report for the first time the development of a novel recombinant antibody specific to full-
length SDF-1. Applied to RIC, we demonstrate a significant decrease in SDF-1α that is at
odds with the literature and suggests a need to investigate the kinetics of full-length SDF-1α
in conditions characterised by tissue hypoxia.
PLOS ONE | https://doi.org/10.1371/journal.pone.0174447 April 5, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Bromage DI, Taferner S, Pillai M, Yellon
DM, Davidson SM (2017) A novel recombinant
antibody specific to full-length stromal derived
factor-1 for potential application in biomarker
studies. PLoS ONE 12(4): e0174447. https://doi.
org/10.1371/journal.pone.0174447
Editor: Shree Ram Singh, National Cancer Institute,
UNITED STATES
Received: January 10, 2017
Accepted: March 9, 2017
Published: April 5, 2017
Copyright: © 2017 Bromage et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by grants from
the British Heart Foundation (BHF PG/15/52/
31598) and National Institute of Health Research
University College London Hospital Biomedical
Research Council (BRC233/CM/SD/101320). Dr.
Daniel Bromage is an MRC Clinical Research
Training Fellow (grant MR/L002043/1). This work
was undertaken at UCLH/UCL, who received a
Introduction
Stromal derived factor-1α (SDF-1α/CXCL12) is a CXC chemokine that is expressed in several
tissues in response to hypoxia, via up-regulation of hypoxia inducible fator-1α (HIF-1α).[1–5]
For example, SDF-1α is up-regulated in experimental and clinical studies of acute myocardial
infarction (MI), wherein it is thought to mitigate adverse ventricular remodelling. Its mecha-
nism of action is reportedly as a chemo-attractant for a variety of cell types expressing its cog-
nate G protein-coupled receptor, CXCR4, including mesenchymal stem cells (MSCs), adipose-
derived regenerative cells, c-kit+ endogenous cardiac stem cells and T lymphocytes,[6–9]
which subsequently have beneficial paracrine effects.[10] It has also been implicated in acute
cardioprotection via its binding to myocardial CXCR4 and subsequent activation of the reper-
fusion injury salvage kinase pathway.[11, 12]
Consequent upon this mechanism, SDF-1α has been evaluated as a potential biomarker in
several cardiovascular contexts, including both as a predictor of incident cardiovascular events
and of adverse outcome. Specifically, studies have investigated SDF-1α in MI with and without
ST segment elevation,[13–16] cardiac surgery,[17] heart failure,[18] patients at increased car-
diovascular risk,[19] and in relation to human heart transplantation.[20] Similarly, remote
ischaemic conditioning (RIC), a technique of cyclical, non-injurious ischaemia applied to an
organ or tissue remote from the heart, has been reported by us and others to increase SDF-1α
as measured using commercially available ELISA kits (typically from R&D Systems, UK).[12]
SDF-1 is cleaved by several peptidases, including leukocyte elastase, matrix metallopro-
teases 1, 2, 3, 9, 13 and 14, and cathepsin G.[21] However, dipeptidyl peptidase 4 (DPP4),
which cleaves SDF-1 at its position 2 proline residue, has been shown to be predominantly
responsible and is the focus here.[22] Cleavage reduces the affinity of SDF-1 for CXCR4, ren-
dering it inactive.[23] Currently, commercial antibodies have different affinities towards intact
SDF-1α (consisting of amino acids 1–67) and DPP4-truncated SDF-1α (amino acids 3–67),
[21, 24] and the kinetics of full-length, active SDF-1α in response to tissue hypoxia are
unknown (Fig 1). Analysis is complicated by the absence of a method to specifically quantify
active SDF-1α in plasma. We therefore aimed to develop a method to investigate intact SDF-
1α, using RIC as an example.
Materials & methods
Ethics statement
All procedures were performed with Local Research Ethics Committee approval at the Hatter
Cardiovascular Institute, University College London (12/0448). Experiments were conducted
according to the principles expressed in the Declaration of Helsinki. Volunteers gave informed
consent. All use of animals was in accordance with the United Kingdom (Scientific Proce-
dures) Act 1986. The experiments were prospectively approved by the UK Home Office animal
research ethics committee under Project Licence number PPL 70/8556, (“Protection of the
Ischaemic and Reperfused Myocardium”) issued to Prof. Derek Yellon in 2015. Adult male
Sprague-Dawley rats weighing 200–250 g (Harlan Laboratories, UK) were euthanized by ter-
minal anaesthesia with 100 mg/kg pentobarbitone sodium administered IP.
Antibody characterisation
A custom human IgG1 bivalent mini-antibody, with embedded FLAG octapeptide and
polyhistidine (His6) tags, was identified from the HuCAL1 (Human Combinatorial
Antibody Library) phage-display library containing several billion, distinct, fully human anti-
bodies.[25, 26] The library was screened using positive selection for binding to the peptide
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KPVSLSYR-Ttds-C derived from the N-terminus of full-length SDF-1(1–8) and negative selec-
tion for binding to the peptide VSLSYR-Ttds-C derived from the N-terminus of cleaved SDF-
1(3–8) (AbD Serotec, UK). These sequences are common to all isoforms of SDF-1 (alpha-
zeta), although SDF-1α is predominant.[27] From the 12 initially identified clones, HCI.SDF1
was identified as having the most specific and robust binding to full-length SDF-1 without any
binding to cleaved SDF-1 or to glucagon-like peptide-1 (GLP-1), an unrelated protein that is
also cleaved by DPP4.
HCI.SDF1 kinetics
To ascertain the association and dissociation kinetics of the antibody, a label-free sensor sys-
tem (Octet Red, ForteBio, UK) was used with SDF-1α, according to the manufacturer’s
instructions. HCI.SDF1 was diluted to 5 μg/ml in 0.1% BSA-PBS supplemented with 0.02%
Tween120 (Sigma-Aldrich, UK). The antibody was immobilised on Amine Reactive Second-
Generation (AR2G) Biosensors (ForteBio, UK) at 30˚C for 180 s before being dipped into the
same buffer containing a range of concentrations of SDF-1α (1 μg/ml with serial twofold dilu-
tions) for 600 s. The sensors were then returned to the buffer for the dissociation reaction, for
600 s. For each concentration of SDF-1α, the kinetic curves for association and dissociation
were obtained and used to calculate a global KD with the analysis programme provided by the
manufacturer (Octet DataAnalysis v9.0.0.12).
HCI.SDF1 ELISA
HCI.SDF1 was optimised as the capture antibody in a sandwich ELISA for measuring full-
length, un-cleaved SDF-1α, with detection by a biotinylated polyclonal goat IgG against the
alpha isoform of human and mouse SDF-1 (BAF310, R&D Systems, UK) and streptavidin-
HRP (R&D Systems, UK). A standard curve was generated using recombinant human (rh)
SDF-1α (R&D Systems, UK) diluted in BUF037A, a diluent with mammalian serum proteins
to mimic the target analyte recovery profile of human plasma (AbD Serotec, UK). Rat SDF-1α
Fig 1. Representation of binding sites of HCI.SDF1α and commercial antibodies on full-length SDF-1α and SDF-1α after cleavage of its N-
terminal di-peptide by DPP4.
https://doi.org/10.1371/journal.pone.0174447.g001
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is 97% identical to the human protein overall, and at the N-terminus is 100% identical to both
human and mouse SDF-1α (Fig 2). The optical density of each well was measured using a 96
well microplate reader (FLUOstar Omega, BMG Labtech, Germany) set to 450 nm. All analy-
ses, including samples and standards, were performed in triplicate to minimise intra-assay var-
iability, and baseline corrected.
In addition, to permit comparison of our novel assay with commercially available antibod-
ies, MAB350, a monoclonal mouse IgG against mouse and human SDF-1α, was substituted as
the detection antibody using the same assay protocol. This antibody was selected based on the
capture antibody used in a commercially available and widely used ELISA for SDF-1α (Quan-
tikine1 ELISA for Human CXCL12, R&D Systems, UK).
To ascertain the sensitivity of each respective assay to intact and cleaved forms of SDF-1α,
human platelet-free plasma was spiked with 3,000 pg/ml intact rhSDF-1α and incubated with
800 μM rhDPP4 (R&D Systems, UK) in Tris buffer for 2 h at 37˚C prior to termination of
DPP4-mediated cleavage with 100 mM Sitagliptin (Merck, US) and mixing known propor-
tions with intact SDF-1α.
Western blotting
Western blot analysis was performed on samples of rhSDF-1α (1–50 ng) denatured in
Laemmli gel sample buffer. HCI.SDF1 was used at a dilution of 1:400 and detected using
1:5000 goat anti-human IgG Fab-FITC (AbD Serotec, Oxon, UK).
Animal experiments
Adult male Sprague-Dawley rats weighing 200–250 g (Harlan Laboratories, UK) were anesthe-
tised with 100 mg/kg intra-peritoneal pentobarbitone sodium. Animals underwent orotracheal
intubation and ventilation using allometrically adjusted tidal volume and ventilation rates, and
supplementary oxygen. Core body temperature was monitored via a rectal temperature sensor
and maintained at 36.5±0.5˚C by adjustment of a homeothermic heat mat (Kent Scientific,
USA). ECG was recorded throughout using PowerLab 4/25 and Animal Bio Amp coupled to
Chart 7 (AD Instruments, UK).
Remote ischaemic conditioning protocol
Animals were randomly assigned to either control or RIC groups. RIC was applied using an
inflatable cuff (Hokanson, USA) around the right hind limb, which was inflated to 200 mmHg
using a manual sphygmomanometer. 3 cycles of 5 min ischaemia and 5 min reperfusion was
applied (Fig 3). Ischaemia was indicated by cyanosis of the right hind limb and confirmed by
global flow assessment with a high resolution laser Doppler imager (Moor Instruments, UK).
Representative images are shown in Fig 4. Control animals underwent a sham procedure,
including identical anaesthetic time. Samples were collected either immediately after RIC or 1
h later (Fig 3), as described below.
Blood collection for SDF-1α and DPP4 measurement
4.5 ml of blood was collected on ice into tubes containing 250 μl of 1 mM Sitagliptin to inhibit
DPP4 and prevent degradation of intact SDF-1α during sample preparation,[21] and 0.5 ml
10x citrate buffer to prevent coagulation. Samples for DPP4 measurement were collected with-
out Sitagliptin. Aspiration of blood was performed by right ventricular puncture using a wide-
bore 19G x 1.5” needle to avoid platelet activation and subsequent release of SDF-1α. Samples
were immediately centrifuged at 1,600 g for 20 min then 10,000 g for 30 min to obtain platelet-
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free plasma and frozen at -80˚C. After all experimental samples were collected they were
defrosted at room temperature and assayed immediately.
To investigate the effect of sample preparation on the measurement of SDF-1α with our
novel assay, separate blood samples were collected in the same way but only centrifuged at
1,600 g for 20 min to obtain unfractionated plasma. Further samples were allowed to clot at
room temperature for 20 min before centrifuging at 1600 g for 10 min to obtain serum.
Human experiments
Six healthy male volunteers participated in the study after giving written informed consent.
None were taking any regular medication. Each volunteer was subjected to RIC, consisting of
3 cycles of 5 min right upper limb ischaemia by inflation of a manual sphygmomanometer to a
pressure of 200 mmHg. Ischaemia was confirmed by absence of a pulse, and presence of pallor
Fig 2. SDF-1α sequence according to species. Alignment of SDF-1α from humans, rats and mice demonstrates the N-terminal sequence is highly
conserved between species. Accession numbers NP_001171605.1, NP_001029055.1 and NP_001012495.1 were used, respectively. Sequences in red
represent the sequence of interest used to generate HCI.SDF1. Blue residues represent differences in the primary sequence between species; note that
none of these are at the N-terminal end.
https://doi.org/10.1371/journal.pone.0174447.g002
Fig 3. In vivo rat protocols. Remote ischaemic conditioning (RIC) was applied to the rat hind limb in the following groups: A) Control: 35 min stabilisation;
B) RIC: 5 min stabilisation, 3 cycles of 5 min ischemia and 5 min reperfusion. Blood samples were taken either immediately after RIC (sample 1) or 60 min
thereafter (sample 2).
https://doi.org/10.1371/journal.pone.0174447.g003
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and paraesthesia. Samples were collected into tubes containing Sitagliptin either immediately
after RIC or 1 hour later via ipsilateral antecubital fossa venepuncture (Fig 3). Experiments
were all conducted at the same time of day.
Statistical methods
On the basis of our previous findings using an in vivo model of RIC, we calculated that a 20%
increase in plasma SDF-1α at a significance level of 0.05 and a power of 0.8 would require 4
animals in each group.[28] Results of animal experiments were compared using the Student t
test for 2 groups of continuous variables and analysis of variance (ANOVA) and Tukey’s Mul-
tiple Comparison Test for 3 or more groups. Data is presented as mean ± SEM. Statistical
significance was reported if P<0.05 using the following nomenclature: P<0.05, P<0.01
and P<0.001. Results where P>0.05 were reported as non-significant (NS). Sample values
were baseline corrected and linear (HCI.SDF1) or nonlinear using log(agonist) versus
response (MAB350) regression of standard values was performed with GraphPad Prism1
version 5.00 for Windows (California, USA).
Results
Identification and characterisation of an ELISA for HCI.SDF1a
A custom, human, monoclonal IgG1 antibody was identified from the HuCAL1 library,
which contains more than 45 billion functional human antibody specificities.[25, 26] The pha-
gemid library was screened for binding to a peptide derived from full-length SDF-1 without
binding to a peptide derived from cleaved SDF-1. HCI.SDF1 was the clone that best satisfied
these criteria and was optimised as the capture antibody in a sandwich ELISA for full-length
SDF-1α. The intra- and inter-assay variations of our ELISA for intact SDF-1α were 2.7% and
7.1% respectively, which are below the recommended maximum threshold of 10%. The limit
of detection (LoD) and limit of quantification (LoQ) in platelet-free plasma were 156 pg/ml
and 312 pg/ml, respectively.
The antibody HCI.SDF1 has comparable binding kinetics to MAB350
The equilibrium dissociation constant (KD) between the recombinant HCI.SDF1 antibody and
SDF-1α was measured using the Octet Red label-free sensor system. Concentrations of 0.98 to
125 nM SDF-1α were measured in parallel wells of a 96 well plate. Curve fits were generated
Fig 4. Laser Doppler blood flow assessment in the subject hind limb during RIC and reperfusion. Panel A shows a colour photograph of the
subject hind limb. Panel B demonstrates complete cessation of blood flow during RIC ischaemia (C) and restoration after reperfusion (D).
https://doi.org/10.1371/journal.pone.0174447.g004
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and a KD calculated for both HCI.SDF1 (1.4 x 10
−8 ± 3.5 x 10−9 M) and MAB350 (8.0 x 10−8 ±
7.0 x 10−9 M), which were not significantly different (n = 3 independent experiments), and
were within the typical range of affinities of monoclonal antibodies. A representative image
from the binding experiment is shown in Fig 5.
HCI.SDF1a is more sensitive to intact SDF-1α
By assaying different proportions of intact and cleaved SDF-1α we were able to demonstrate
that an ELISA using HCI.SDF1 as the capture antibody is specific for full-length SDF-1α,
whereas commercial assays report a combination of intact and cleaved SDF-1α (Fig 6), making
the results with commercial assays difficult to interpret.
Further analysis demonstrated that HCI.SDF1 is able to detect denatured SDF-1α and is
therefore suitable for Western blot applications (Fig 7).
Serum preparation dramatically increases SDF-1α levels
The effect of blood sample preparation on SDF-1α levels was determined using rat platelet-
free plasma compared to serum and plasma from which platelets had not been removed
(unfractionated plasma). SDF-1α levels were significantly higher in serum samples than either
platelet-free or unfractionated plasma samples, when measured by ELISA with either HCI.
SDF1 (5000 ± 200 pg/ml, 1150 ± 160 pg/ml & 1140 ± 190 pg/ml, respectively, n = 3–7,
P<0.001) or a commercial assay (4400 ± 300 pg/ml, 490 ± 30 pg/ml & 1150 ± 140 pg/ml,
respectively, n = 3–4, P<0.001; Fig 8). When serum samples were taken from animals with
and without RIC, there was no significant difference between control and RIC groups. There-
fore, platelet-free plasma samples were used in all subsequent analyses.
Plasma levels of full-length SDF-1α decrease after RIC
An ELISA using MAB350 (R&D Systems, UK), a monoclonal mouse IgG against mouse and
human SDF-1α that is used in most reported studies of SDF-1α replicated our previously
reported finding that SDF-1α is significantly increased by an RIC stimulus in rats,[12] and this
difference was still present 1 h after the RIC protocol (Fig 9). However, when measured using
HCI.SDF1, levels of full-length SDF-1α were unexpectedly found to significantly decrease
immediately after RIC (670 ± 130 pg/ml vs. 1150 ± 160 pg/ml, n = 7–9, P<0.05) although they
normalised by 1 h (910 ± 110 pg/ml vs. 950 ± 90 pg/ml, n = 4, P = NS).
To confirm our findings in humans, we repeated the RIC protocol on the upper limb of 6
healthy human volunteers and, despite significant inter-individual variability, found a similar
trend towards a reduction in active SDF-1α (pre-RIC 380.0±154.9 pg/ml; 0 min 337.5±148.3
pg/ml; 60 min 329.8±148.7 pg/ml, P for trend<0.05, Fig 10).
Discussion
Several studies have associated increased SDF-1α with both increased risk of incident cardio-
vascular events and subsequent adverse outcome. For example, in Framingham Heart Study
patients, circulating SDF-1α was significantly associated with both new-onset heart failure and
all-cause mortality in a multi-variable regression model.[19] SDF-1α was not associated with
MI in this study, although genome-wide association studies (GWAS) have identified SDF-1α
as a risk locus for both coronary artery disease and MI.[29] Furthermore, in patients with
chronic kidney disease, who are at high risk for cardiovascular events, SDF-1α was signifi-
cantly associated with MI and all-cause mortality.[30] Circulating SDF-1α has also been asso-
ciated with worse left ventricular (LV) function in patients hospitalised with heart failure.[18]
A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies
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With respect to the prediction of adverse sequelae after cardiovascular events, elevated
SDF-1α has been reported after MI in several studies. [13–16] In ST segment elevation MI
(STEMI), higher SDF-1α levels predicted worse LV performance, Killip score and 30 day mor-
tality.[13] SDF-1α levels have also been used to predict adverse events in stable patients with a
history of MI [15] and patients with non-STEMI, where SDF-1α levels were an independent
predictor of death, MI and heart failure.[16]
Several studies have recorded increased SDF-1α following RIC, as measured with commer-
cially available ELISA kits. For example, Jiang et al. demonstrated increased serum and myo-
cardial SDF-1α after a remote ischaemic postconditioning protocol consisting of clamping the
infra-renal abdominal aorta for 4 cycles of 5 min ischaemia and 5 min reperfusion. SDF-1ɑ
levels peaked at 1 hour, with an 80±5% increase (P<0.001) compared to control (sham sur-
gery) animals.[31] Interestingly, they measured SDF-1α in serum samples, which our findings
indicate would result in artefactually high levels of SDF-1α compared to plasma. In a similar
experiment, Kamota et al. conferred RIC using repetitive occlusion of the abdominal aorta in
mice prior to ischaemia-reperfusion of the left anterior descending (LAD) coronary artery ter-
ritory. Using a standard ELISA, they measured 4-fold levels of SDF-1α after 1 hour in platelet-
poor plasma samples.[32] Our group also showed that circulating SDF-1α levels were altered
Fig 5. Representative HCI.SDF1 and MAB350 binding kinetics data. Representative data obtained from label-free sensor evaluation of HCI.SDF1 and
MAB350 with Amine Reactive Second-Generation (AR2G) Biosensors.
https://doi.org/10.1371/journal.pone.0174447.g005
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in rats subjected to 3 cycles of 5 min hind-limb ischaemia and reperfusion, increasing by 50%
in platelet-free plasma samples to a peak of 890±70 pg/ml.[12]
However, not all studies have reported increased SDF-1α in conditions characterised by tis-
sue hypoxia. Fortunato et al. showed a reduction in serum SDF-1α in patients after MI,
Fig 6. ELISA for intact and cleaved SDF-1α using HCI.SDF1 and MAB350. An ELISA assay demonstrates that HCI.
SDF1 is specific for active SDF-1α, with very low signal in the absence of intact SDF-1α, whereas there is substantial
residual signal in the absence of intact SDF-1αwhen using the commercial antibody MAB350.
https://doi.org/10.1371/journal.pone.0174447.g006
Fig 7. HCI.SDF1 used for Western blotting. Western blots demonstrated a concentration-signal relationship when HCI.SDF1 was used to detect
varying concentrations of rhSDF-1α.
https://doi.org/10.1371/journal.pone.0174447.g007
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although higher levels were associated with more adverse events,[14] and Damas et al. demon-
strated a significant reduction of plasma SDF-1α in patients with stable and unstable angina
compared to healthy controls.[33] The investigation of SDF-1α as a biomarker is confounded
because the aforementioned studies use the commercially available ELISA from R&D Systems
that employs the monoclonal mouse IgG, MAB350. The present study shows that this antibody
has different affinity towards full-length and DPP4-cleaved SDF-1α. Baerts et al. also observed
a significant reduction in immunoreactivity after they measured DPP4-cleaved, recombinant
SDF-1α using several different commercial ELISA kits (including R&D Systems, Raybiotech
and Peprotech).[11] We observed a partial, but incomplete, loss of signal in an ELISA assay
using MAB350 following complete cleavage of SDF-1α with DPP4. This might be explained
by altered binding affinity of MAB350 or of the polyclonal detection antibody (BAF310) used
in this sandwich ELISA format after cleavage of SDF-1α. As loss of the N-terminal Lys1 is
known to confer a complete loss of bioreactivity,[23] the incomplete detection of SDF-1α by
Fig 8. The effect of sample type on SDF-1α concentration. Serum samples, collected by allowing whole blood to clot for 10 min prior to centrifuging to
remove the clot, had significantly more active SDF-1α than either platelet-free (PFP) or unfractionated plasma samples that were collected into a citrated
tube and prepared by differential centrifugation, when measured using either capture antibody as indicated.
https://doi.org/10.1371/journal.pone.0174447.g008
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commercial antibodies confounds interpretation of both basic and clinical studies of SDF-1α
that have used commercially available ELISA assays.
Accurate measurement is crucial given the growing interest in SDF-1α both as a potential
biomarker and therapy for ischaemic cardiomyopathy.[34–38] Baerts et al. recognised that ex
vivo truncation of SDF-1α significantly affects plasma SDF-1α measurement.[21] Using tubes
treated with DPP4 inhibitors they collected plasma samples from patients with heart failure
and associated SDF-1α level with heart failure severity, according to ejection fraction. The
present study goes further and we report for the first time the application of a novel antibody
against the N-terminal Lys1, that has similar binding kinetics to commercially available anti-
bodies, in an immunoassay that is specific for intact, active SDF-1. This antibody consequently
has greater utility in the investigation of SDF-1α in a variety of settings, when combined with a
detection antibody specific to the alpha isoform. Furthermore, as HCI.SDF1 is a recombinant
antibody, it is consistent with a reductionist approach to animal experimentation.[39]
In an interesting approach to this problem, Wang et al. recently developed a method
to quantify intact and cleaved SDF-1α using mass spectrometry.[40] They reported a LoQ
of 20 pmol/L to 20 nmol/L in human plasma and, importantly, they demonstrated the
Fig 9. Effect of RIC on intact and cleaved SDF-1α. Following RIC, ELISA using commercial antibodies detects an increase in plasma SDF-1α
levels whereas HCI.SDF1α, which is more specific for full-length SDF-1α, measures a decrease immediately after RIC that is restored to baseline by
1 h.
https://doi.org/10.1371/journal.pone.0174447.g009
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differentiation of intact from cleaved SDF-1α to be critical in the investigation of biomarkers
of DPP4 efficacy. Using their assay, they report circulating SDF-1α in mice and primates to be
in the range detectable by HCI.SDF1 (760 pg/ml and 310 pg/ml, respectively), although they
did not report baseline levels in humans. The novel assay described in the present paper has
the added advantage of being easy and relatively cost-effective to perform.
Using HCI.SDF1, we first demonstrated that SDF-1α levels are dramatically increased in
serum, compared to platelet-free and platelet-poor plasma samples. SDF-1α is known to be
contained in platelet granules and be expressed upon platelet activation,[41] as occurs during
the preparation of serum samples. The observations we made on changes in SDF-1α levels
could not be detected when using serum samples, due to this high background level of SDF-
1α. It is therefore important to ensure correct sample preparation when measuring SDF-1α.
Published results using existing commercially available assays for SDF-1α are highly variable.
Fig 10. Effect of RIC on intact SDF-1α in humans. Plasma levels of full-length SDF-1α (quantified using HCI.SDF1α ELISA), decreased significantly in
healthy male volunteers subjected to RIC.
https://doi.org/10.1371/journal.pone.0174447.g010
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Examination of the methods used in these studies reveals highly variable protocols, which
include the analysis of both serum and plasma samples.[13, 42, 43]
As an example, we have challenged the existing paradigm that SDF-1α is up-regulated in
response to RIC, finding instead a significant decrease in active SDF-1α after RIC. Combined
with our previous observation that SDF-1α levels appear to increase when measured with com-
mercial assays, this would suggest that there is, in fact, an increase in cleaved, inactive SDF-1α.
To confirm this unanticipated finding we repeated the study in healthy human volunteers and
observed a similar decrease in SDF-1α levels after RIC, despite there being significant variabil-
ity in baseline SDF-1α measurements between individuals. Previously, circulating SDF-1α var-
iability has been associated with various factors including waist circumference,[44] time of day
and acute stress.[45] We did not find any significant association between waist circumference
and baseline SDF-1α; all experiments were performed at the same time of day to account for
SDF-1α circadian rhythm; and no major difference in stress levels of the subjects was apparent,
although this was not specifically controlled for.
HCI.SDF1 also has potential value in the investigation of other isoforms of SDF-1. All iso-
forms are known to agonise CXCR4 but have distinct properties. For example, SDF-1β is more
resistant than SDF-1α to proteolysis.[46] Interestingly, expression of SDF-1ɣ has recently been
reported in less vascular organs that are susceptible to infarction, including the heart.[46]
However, the predominant and best described isoform is SDF-1α.[27]
Conclusions
SDF-1α is ostensibly increased by RIC, a manoeuvre that has been associated with acute and
chronic cardioprotection. However, by using an antibody specific to the intact, active form of
SDF-1α we have shown that RIC reduces circulating SDF-1α, which we hypothesise is due to
its cleavage, a finding we replicated in both rats and humans. This has implications for the
increasing number of studies exploring the potential of SDF-1α as a biomarker in a range of
cardiovascular contexts. Further studies are necessary to fully elucidate the value of HCI.SDF1
as a biomarker in relation to clinical phenotypes.
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